Literature DB >> 11549531

Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease.

D E O'Donnell1, S M Revill, K A Webb.   

Abstract

The role of dynamic hyperinflation (DH) in exercise limitation in chronic obstructive pulmonary disease (COPD) remains to be defined. We examined DH during exercise in 105 patients with COPD (FEV(1) = 37 +/- 13% predicted; mean +/- SD) and studied the relationships between resting lung volumes, DH during exercise, and peak oxygen consumption (VO(2)). Patients completed pulmonary function tests and incremental cycle exercise tests. We measured the change in inspiratory capacity (Delta IC) during exercise to reflect changes in DH. During exercise, 80% of patients showed significant DH above resting values. IC decreased 0.37 +/- 0.39 L or 14 +/- 15% predicted during exercise (p < 0.0005), but with large variation in range. Delta IC correlated best with resting IC, both expressed %predicted (r = -0.50, p < 0.0005). Peak VO(2) (%predicted maximum) correlated best with the peak tidal volume attained (VT standardized as % of predicted vital capacity) (r = 0.68, p < 0.0005), which, in turn, correlated strongly with IC at peak exercise (r = 0.79, p < 0.0005) or at rest (r = 0.75, p < 0.0005). The extent of DH during exercise in COPD correlated best with resting IC. DH curtailed the VT response to exercise. This inability to expand VT in response to increasing metabolic demand contributed importantly to exercise intolerance in COPD.

Entities:  

Mesh:

Year:  2001        PMID: 11549531     DOI: 10.1164/ajrccm.164.5.2012122

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  173 in total

Review 1.  Alternatives to lung transplantation: lung volume reduction for COPD.

Authors:  Gerard J Criner
Journal:  Clin Chest Med       Date:  2011-06       Impact factor: 2.878

2.  Ventilatory responses to prolonged exercise with heavy load carriage.

Authors:  Devin B Phillips; Michael K Stickland; Stewart R Petersen
Journal:  Eur J Appl Physiol       Date:  2015-08-14       Impact factor: 3.078

3.  Continuous and intermittent exercise responses in individuals with chronic obstructive pulmonary disease.

Authors:  S Sabapathy; R A Kingsley; D A Schneider; L Adams; N R Morris
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

Review 4.  [Chronic bronchitis, COPD].

Authors:  H R Wirtz
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

5.  Effect of inspiratory muscle work on peripheral fatigue of locomotor muscles in healthy humans.

Authors:  Lee M Romer; Andrew T Lovering; Hans C Haverkamp; David F Pegelow; Jerome A Dempsey
Journal:  J Physiol       Date:  2005-12-22       Impact factor: 5.182

6.  Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease.

Authors:  I Vogiatzis; O Georgiadou; S Golemati; A Aliverti; E Kosmas; E Kastanakis; N Geladas; A Koutsoukou; S Nanas; S Zakynthinos; C Roussos
Journal:  Thorax       Date:  2005-06-17       Impact factor: 9.139

Review 7.  Chronic obstructive pulmonary disease.

Authors:  N R Anthonisen
Journal:  Can Respir J       Date:  2007-10       Impact factor: 2.409

8.  Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? NO.

Authors:  Shawn D Aaron
Journal:  Can Fam Physician       Date:  2007-08       Impact factor: 3.275

9.  Respiratory kinematics by optoelectronic plethysmography during exercise in men and women.

Authors:  Ioannis Vogiatzis; Andrea Aliverti; Spyretta Golemati; Olga Georgiadou; Antonella Lomauro; Epaminondas Kosmas; Emmanouil Kastanakis; Charis Roussos
Journal:  Eur J Appl Physiol       Date:  2004-12-01       Impact factor: 3.078

10.  Effect of obesity on constant workrate exercise in hyperinflated men with COPD.

Authors:  Louis Laviolette; Francesco Sava; Denis E O'Donnell; Katherine A Webb; Alan L Hamilton; Steven Kesten; François Maltais
Journal:  BMC Pulm Med       Date:  2010-05-30       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.